The results of the trial suggested that MDV3100 inhibits proliferation of breast cancer cells.
The results demonstrated that androgens dihydrotestosterone (DHT) or R1881 treatment had a proliferative effect on breast cancer cells which was blocked by MDV3100.
However, MDV3100 also blocked estrogen-mediated proliferation of breast cancer cells.
Lead study investigator Jennifer Richer said these preclinical data show that MDV3100 suppresses androgen-driven breast cancer cell growth and, surprisingly, also suppresses estrogen-driven breast cancer cell growth.
Medivation chief medical officer Lynn Seely said the proven activity of MDV3100 against the androgen receptor and these intriguing new preclinical data suggesting potential activity against estrogen-mediated pathways suggest that MDV3100 may have therapeutic utility in breast cancer, something that would of course need to be investigated through clinical trials.